三期试验验证首款mRNA癌症疫苗 递送与政策挑战浮现在欧洲肿瘤内科学会大会上公布的一项三期临床试验证实，与帕博利珠单抗单药治疗相比，个性化新抗原mRNA疗法因蒂斯梅兰奥托基因将复发或死亡风险降低了42%。
Phase 3 Trial Validates First mRNA Cancer Vaccine as Delivery and Policy Challenges Emerge A Phase 3 clinical trial presented at the European Society for Medical Oncology Congress demonstrated that the personalized neoantigen mRNA therapy intismeran autogene reduced the risk of recurrence or death by 42% compared to pembrolizumab alone.
尽管这标志着首个达到三期肿瘤学终点的mRNA疗法，但行业专家强调，仍存在阻碍该疗法广泛临床应用的重大结构性障碍。
While marking the first mRNA therapy to meet a Phase 3 oncology endpoint, industry experts highlight substantial structural barriers preventing widespread clinical adoption.
关键瓶颈包括：传统监管路径难以适应个体化疗法、递送环节分散、支付方报销模式错位，以及临床指南更新迟缓。
Key bottlenecks include traditional regulatory pathways poorly suited for individualized therapeutics, fragmented delivery chains, misaligned payer reimbursement models, and sluggish clinical guidelines.
为应对试验网络和标准化方面的挑战，美国国家癌症研究所和美国国立卫生研究院基金会正在设立一项耗资2亿美元的公私合作“治疗性癌症疫苗计划”。
To address trial network and standardisation hurdles, the National Cancer Institute and Foundation for the NIH are establishing a forthcoming $200 million public-private Therapeutic Cancer Vaccines Initiative.